Cargando…
Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
BACKGROUND: Lung cancer has the highest incidence among solid tumors in men and is the third most common cancer in women. Despite improved understanding of genomic and mutational landscape in non-small cell lung cancer (NSCLC), the five-year survival in these patients has remained stagnant at a dism...
Autores principales: | Chen, Shu-Chen, Diao, Yu-Zhu, Zhao, Zi-Han, Li, Xiao-Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293907/ https://www.ncbi.nlm.nih.gov/pubmed/32606939 http://dx.doi.org/10.2147/CMAR.S245257 |
Ejemplares similares
-
Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy
por: Sun, Wei, et al.
Publicado: (2017) -
Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020) -
Knockdown lncRNA DLEU1 Inhibits Gliomas Progression and Promotes Temozolomide Chemosensitivity by Regulating Autophagy
por: Lv, Qiao-Li, et al.
Publicado: (2020) -
Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin
por: Xu, Xiaohui, et al.
Publicado: (2020) -
Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)